Gray, H., Bell-McGuinn, K., Fleming, G., Cristea, M., Xiong, H., Sullivan, D., … Martin, L. (2018). Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2017.12.029 (Original work published 2018)